Haemonetics Corporation updated revenue guidance for the year 2023. For the period, The Company updated its previous fiscal 2023 GAAP total revenue growth guidance from 8% - 11% to 12% - 15% and its fiscal 2023 organic revenue growth guidance as follows: total revenue of 15% - 18% against previous guidance of 10% - 14%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
95.38 USD | +1.04% | +4.24% | +11.54% |
Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.54% | 4.79B | |
-4.02% | 184B | |
-0.75% | 108B | |
-2.97% | 67.82B | |
+4.48% | 51.05B | |
+9.09% | 44.67B | |
+3.40% | 41.78B | |
+3.12% | 26.78B | |
+4.10% | 26.59B | |
+15.23% | 25.86B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Updates Revenue Guidance for the Year 2023